Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Last Updated: September 26, 2022

Patent: 4,743,552

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Summary for Patent: 4,743,552
Title: Method for growth in tissue culture of normal colonic epithelial cells and method for determination of preneoplastic color cells
Abstract:The invention concerns a method for the routine primary culture of human colonic epithelial cells within a monolayer. 12-0-tetradecanoylphorbol-13-acetate (TPA) enhanced DNA synthesis an average of 8 fold when assayed by [.sup.3 h]dThd labeling indices (L.I.) in colonic epithelial cells from familial polyposis patients and in tubular adenomas. No such stimulation by TPA was seen in cells from high-risk patients without familial polyposis, or in cells from low-risk subjects.
Inventor(s): Friedman; Eileen A. (New York, NY), Lipkin; Martin (New York, NY)
Assignee: Sloan-Kettering Institute for Cancer Research (New York, NY)
Application Number:06/655,090
Patent Claims:see list of patent claims

Details for Patent 4,743,552

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 05/05/2004 See Plans and Pricing 2039-03-29
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 12/02/2004 See Plans and Pricing 2039-03-29
Amphastar Pharmaceuticals, Inc. AMPHADASE hyaluronidase Injection 021665 10/26/2004 See Plans and Pricing 2039-03-29
Akorn, Inc. HYDASE hyaluronidase Injection 021716 10/25/2005 See Plans and Pricing 2039-03-29
Smith & Nephew, Inc. SANTYL collagenase Ointment 101995 06/04/1965 See Plans and Pricing 2039-03-29
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.